Novo Nordisk A/S (NVO)
123.90
-0.61
(-0.49%)
USD |
NYSE |
Apr 15, 16:00
123.29
-0.61
(-0.49%)
Pre-Market: 05:57
Novo Nordisk Research and Development Expense (Quarterly): 1.510B for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 1.510B |
| September 30, 2023 | 1.187B |
| June 30, 2023 | 1.042B |
| March 31, 2023 | 970.27M |
| December 31, 2022 | 1.111B |
| September 30, 2022 | 762.61M |
| June 30, 2022 | 733.41M |
| March 31, 2022 | 785.33M |
| December 31, 2021 | 866.26M |
| September 30, 2021 | 674.11M |
| June 30, 2021 | 639.17M |
| March 31, 2021 | 639.35M |
| December 31, 2020 | 718.12M |
| September 30, 2020 | 614.39M |
| June 30, 2020 | 486.02M |
| March 31, 2020 | 557.60M |
| December 31, 2019 | 649.91M |
| September 30, 2019 | 536.43M |
| June 30, 2019 | 535.14M |
| March 31, 2019 | 407.57M |
| December 31, 2018 | 694.69M |
| September 30, 2018 | 568.25M |
| June 30, 2018 | 528.13M |
| March 31, 2018 | 547.88M |
| December 31, 2017 | 630.23M |
| Date | Value |
|---|---|
| September 30, 2017 | 525.94M |
| June 30, 2017 | 504.80M |
| March 31, 2017 | 471.18M |
| December 31, 2016 | 648.16M |
| September 30, 2016 | 518.52M |
| June 30, 2016 | 505.69M |
| March 31, 2016 | 488.49M |
| December 31, 2015 | 591.57M |
| September 30, 2015 | 489.80M |
| June 30, 2015 | 449.39M |
| March 31, 2015 | 492.25M |
| December 31, 2014 | 648.56M |
| September 30, 2014 | 649.75M |
| June 30, 2014 | 565.08M |
| March 31, 2014 | 581.56M |
| December 31, 2013 | 650.72M |
| September 30, 2013 | 496.71M |
| June 30, 2013 | 475.60M |
| March 31, 2013 | 470.21M |
| December 31, 2012 | 558.17M |
| September 30, 2012 | 439.34M |
| June 30, 2012 | 442.56M |
| March 31, 2012 | 442.05M |
| December 31, 2011 | 498.30M |
| September 30, 2011 | 429.23M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
486.02M
Minimum
Jun 2020
1.510B
Maximum
Dec 2023
790.41M
Average
718.12M
Median
Dec 2020
Research and Development Expense (Quarterly) Benchmarks
| Amgen Inc | 1.534B |
| AstraZeneca PLC | 3.073B |
| Sanofi SA | 2.016B |
| Viking Therapeutics Inc | 20.50M |
| Evaxion Biotech AS | 2.298M |